We updated the design of this site on December 18, 2017. Learn more.
ClinicalTrials.gov Menu

Effects of Epinephrine and Intravenous (I.V.) Needle on Cardiopulmonary Resuscitation (CPR) Outcome

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00121524
Recruitment Status : Completed
First Posted : July 21, 2005
Last Update Posted : May 29, 2015
Laerdal Medical
Ullevaal University Hospital
Health Region East, Norway
Norwegian Air Ambulance Foundation
University of Oslo
Information provided by (Responsible Party):
Petter Andreas Steen, University of Oslo

Brief Summary:
Intravenous epinephrine has been part of the guidelines for cardiopulmonary resuscitation since the start. It improves outcome in animal studies, but has never been investigated in a controlled study in humans. Epidemiologic data indicate that it is an independent negative predictor for survival. If this is true in a controlled randomized study, it could be due to effects of the drug itself or more likely due to reduced quality of chest compressions and ventilations due to the time spent on placing an I.V. needle and injecting drugs.

Condition or disease Intervention/treatment Phase
Cardiac Arrest Drug: Epinephrine Device: Intravenous needle Drug: Atropine Drug: Amiodarone Phase 2

Detailed Description:
In a randomized, controlled study of all out-of-hospital cardiac arrest patients in Oslo, Norway, half the patients are treated according to the international guidelines for advanced CPR, and the other half according to the same guidelines, except for no I.V. needle or drugs are given until 5 minutes after eventual return of spontaneous circulation.

Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 904 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Effects of Epinephrine and I.V. Needle on CPR Outcome
Study Start Date : January 2003
Primary Completion Date : May 2008
Study Completion Date : June 2008

Arm Intervention/treatment
Experimental: IV yes
Intravenous needle Epinephrine q 3 min during CPR Atropine 3 mg in initial asystole Amiodarone 300 mg iv after repeated failed defibrillation attempts
Drug: Epinephrine
Epinephrine 1 mg is given iv. every 3 min during CPR
Other Name: Adrenaline
Device: Intravenous needle
An intravenous needle in placed as soon as possible during CPR
Drug: Atropine
Atropine 3 mg iv in initial systole
Other Name: Atropine sulfate
Drug: Amiodarone
amiodarone 300 mg iv after repeated failed defibrillation attempts
Other Name: Amiodaron
No Intervention: IV no
The patient will not have an intravenous needle placed or given any drugs during CPR. If patient obtains spontaneous circulation, an intravenous needle is placed and patient can receive any drugs that are appropriate during the following treatment.

Primary Outcome Measures :
  1. survival to hospital discharge with neurologic outcome [ Time Frame: discharge from hospital ]

Secondary Outcome Measures :
  1. admit to hospital with spontaneous circulation [ Time Frame: hospital admission ]
  2. one year survival with neurologic outcome [ Time Frame: one year after hospital discharge ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Cardiac arrest out-of-hospital

Exclusion Criteria:

  • <18 years old
  • Trauma as cause of arrest

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00121524

Ulleval University Hospital
Oslo, Norway, N-0407
Sponsors and Collaborators
Petter Andreas Steen
Laerdal Medical
Ullevaal University Hospital
Health Region East, Norway
Norwegian Air Ambulance Foundation
University of Oslo
Principal Investigator: Lars Wik, MD, PhD Ullevaal University Hospital

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Responsible Party: Petter Andreas Steen, Professor Acute Medicine, University of Oslo
ClinicalTrials.gov Identifier: NCT00121524     History of Changes
Other Study ID Numbers: 525-02201
First Posted: July 21, 2005    Key Record Dates
Last Update Posted: May 29, 2015
Last Verified: May 2015

Keywords provided by Petter Andreas Steen, University of Oslo:
cardiac arrest

Additional relevant MeSH terms:
Heart Arrest
Heart Diseases
Cardiovascular Diseases
Epinephryl borate
Adrenergic alpha-Agonists
Adrenergic Agonists
Adrenergic Agents
Neurotransmitter Agents
Molecular Mechanisms of Pharmacological Action
Physiological Effects of Drugs
Adrenergic beta-Agonists
Bronchodilator Agents
Autonomic Agents
Peripheral Nervous System Agents
Anti-Asthmatic Agents
Respiratory System Agents
Vasoconstrictor Agents
Adjuvants, Anesthesia
Anti-Arrhythmia Agents
Muscarinic Antagonists
Cholinergic Antagonists
Cholinergic Agents
Vasodilator Agents